Current perspectives in the management of sepsis and septic shock

被引:2
作者
Chiscano-Camon, Luis [1 ,2 ,3 ]
Ruiz-Sanmartin, Adolf [1 ,2 ]
Bajana, Ivan [1 ,2 ]
Bastidas, Juliana [1 ,2 ]
Lopez-Martinez, Rocio [4 ]
Franco-Jarava, Clara [4 ]
Gonzalez, Juan Jose [5 ]
Larrosa, Nieves [5 ]
Riera, Jordi [1 ,2 ]
Nuvials-Casals, Xavier [1 ,2 ]
Ruiz-Rodriguez, Juan Carlos [1 ,2 ,3 ]
Ferrer, Ricard [1 ,2 ,3 ]
机构
[1] Vall dHebron Barcelona Hosp Campus, Intens Care Dept, Vall dHebron Univ Hosp, Barcelona, Spain
[2] Vall dHebron Univ Hosp, Vall dHebron Barcelona Hosp Campus, Vall dHebron Res Inst VHIR, Shock Organ Dysfunct & Resuscitat Res Grp, Barcelona, Spain
[3] Univ Autonoma Barcelona, Dept Med, Barcelona, Spain
[4] Vall dHebron Barcelona Hosp Campus, Immunol Dept, Vall dHebron Hosp Univ, Barcelona, Spain
[5] Vall Dhebron Univ Hosp, Vall Dhebron Barcelona Hosp Campus, Microbiol Dept, Barcelona, Spain
关键词
septic shock; precision medicine; personalized treatment; treatable trait; hemoadsorption; cytokine storm; sepsis phenotypes; MULTIPLE ORGAN FAILURE; ANGIOTENSIN-II; 28-DAY MORTALITY; ASCORBIC-ACID; VITAMIN-C; THERAPY; ADRENOMEDULLIN; HYDROCORTISONE; ACTIVATION; ADULTS;
D O I
10.3389/fmed.2024.1431791
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Within patients with sepsis, there exists significant heterogeneity, and while all patients should receive conventional therapy, there are subgroups of patients who may benefit from specific therapies, often referred to as rescue therapies. Therefore, the identification of these specific patient subgroups is crucial and lays the groundwork for the application of precision medicine based on the development of targeted interventions. Over the years, efforts have been made to categorize sepsis into different subtypes based on clinical characteristics, biomarkers, or underlying mechanisms. For example, sepsis can be stratified into different phenotypes based on the predominant dysregulated host response. These phenotypes can range from hyperinflammatory states to immunosuppressive states and even mixed phenotypes. Each phenotype may require different therapeutic approaches to improve patient outcomes. Rescue strategies for septic shock may encompass various interventions, such as immunomodulatory therapies, extracorporeal support (e.g., ECMO), or therapies targeted at specific molecular or cellular pathways involved in the pathophysiology of sepsis. In recent years, there has been growing interest in precision medicine approaches to sepsis and phenotype identification. Precision medicine aims to tailor treatments to each individual patient based on their unique characteristics and disease mechanisms.
引用
收藏
页数:13
相关论文
共 110 条
  • [91] Cytokine Hemoadsorption as Rescue Therapy for Critically Ill Patients With SARS-CoV-2 Pneumonia With Severe Respiratory Failure and Hypercytokinemia
    Ruiz-Rodriguez, Juan Carlos
    Chiscano-Camon, Luis
    Ruiz-Sanmartin, Adolf
    Palmada, Clara
    Paola Plata-Menchaca, Erika
    Franco-Jarava, Clara
    Perez-Carrasco, Marcos
    Hernandez-Gonzalez, Manuel
    Ferrer, Ricard
    [J]. FRONTIERS IN MEDICINE, 2022, 8
  • [92] Vasopressin versus norepinephrine infusion in patients with septic shock
    Russell, James A.
    Walley, Keith R.
    Singer, Joel
    Gordon, Anthony C.
    Hebert, Paul C.
    Cooper, D. James
    Holmes, Cheryl L.
    Mehta, Sangeeta
    Granton, John T.
    Storms, Michelle M.
    Cook, Deborah J.
    Presneill, Jeffrey J.
    Ayers, Dieter
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (09) : 877 - 887
  • [93] Low-dose corticosteroids for adult patients with septic shock: a systematic review with meta-analysis and trial sequential analysis
    Rygard, Sofie Louise
    Butler, Ethan
    Granholm, Anders
    Moller, Morten Hylander
    Cohen, Jeremy
    Finfer, Simon
    Perner, Anders
    Myburgh, John
    Venkatesh, Balasubramanian
    Delaney, Anthony
    [J]. INTENSIVE CARE MEDICINE, 2018, 44 (07) : 1003 - 1016
  • [94] The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: A randomized controlled trial
    Schaedler, Dirk
    Pausch, Christine
    Heise, Daniel
    Meier-Hellmann, Andreas
    Brederlau, Joerg
    Weiler, Norbert
    Marx, Gernot
    Putensen, Christian
    Spies, Claudia
    Joerres, Achim
    Quintel, Michael
    Engel, Christoph
    Kellum, John A.
    Kuhlmann, Martin K.
    [J]. PLOS ONE, 2017, 12 (10):
  • [95] Can the cytokine adsorber CytoSorb(R) help to mitigate cytokine storm and reduce mortality in critically ill patients? A propensity score matching analysis
    Scharf, Christina
    Schroeder, Ines
    Paal, Michael
    Winkels, Martin
    Irlbeck, Michael
    Zoller, Michael
    Liebchen, Uwe
    [J]. ANNALS OF INTENSIVE CARE, 2021, 11 (01)
  • [96] Adsorption therapy in critically ill with septic shock and acute kidney injury: a retrospective and prospective cohort study
    Schittek, Gregor A.
    Zoidl, Philipp
    Eichinger, Michael
    Orlob, Simon
    Simonis, Holger
    Rief, Martin
    Metnitz, Philipp
    Fellinger, Tobias
    Soukup, Jens
    [J]. ANNALS OF INTENSIVE CARE, 2020, 10 (01)
  • [97] FDA Approval of Angiotensin II for the Treatment of Hypotension in Adults with Distributive Shock
    Senatore, Fortunato
    Jagadeesh, Gowraganahalli
    Rose, Martin
    Pillai, Venkateswaran C.
    Hariharan, Sudharshan
    Liu, Ququan
    Tzu-Yun, McDowell
    Sapru, Mohan K.
    Southworth, Mary Ross
    Stockbridge, Norman
    [J]. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2019, 19 (01) : 11 - 20
  • [98] Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
    Seymour, Christopher W.
    Kennedy, Jason N.
    Wang, Shu
    Chang, Chung-Chou H.
    Elliott, Corrine F.
    Xu, Zhongying
    Berry, Scott
    Clermont, Gilles
    Cooper, Gregory
    Gomez, Hernando
    Huang, David T.
    Kellum, John A.
    Mi, Qi
    Opal, Steven M.
    Talisa, Victor
    van der Poll, Tom
    Visweswaran, Shyam
    Vodovotz, Yoram
    Weiss, Jeremy C.
    Yealy, Donald M.
    Yende, Sachin
    Angus, Derek C.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (20): : 2003 - 2017
  • [99] Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial
    Shakoory, Bita
    Carcillo, Joseph A.
    Chatham, W. Winn
    Amdur, Richard L.
    Zhao, Huaqing
    Dinarello, Charles A.
    Cron, Randall Q.
    Opal, Steven M.
    [J]. CRITICAL CARE MEDICINE, 2016, 44 (02) : 275 - 281
  • [100] Potential survival benefit and early recovery from organ dysfunction with polymyxin B hemoperfusion: perspectives from a real-world big data analysis and the supporting mechanisms of action
    Shoji, Hisataka
    Ferrer, Ricard
    [J]. JOURNAL OF ANESTHESIA ANALGESIA AND CRITICAL CARE, 2022, 2 (01):